Bryan Hammar, DO
Family Medicine · Rigby, IDNPI 1841219987
Payments from drug & device makers
Across 259 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$555
- Sanofi-aventis U.S. LLC$188
- Novo Nordisk$140
- Pfizer$106
- Vanda Pharmaceuticals Inc.$98
- plus $999 from 24 others
What the payments were for
- Food & beverage$3,961100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 119 | $1,875 |
| Amgen | 43 | $555 |
| Sanofi-aventis U.S. LLC | 12 | $188 |
| Novo Nordisk | 10 | $140 |
| Pfizer | 6 | $106 |
| Vanda Pharmaceuticals Inc. | 4 | $98 |
| Lilly USA, LLC | 7 | $94 |
| GSK | 6 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $81 |
| Novartis | 3 | $76 |
| Mylan Specialty L.p. | 4 | $68 |
| Sanofi Pasteur Inc. | 4 | $66 |
| Corium, LLC | 5 | $58 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Amarin Pharma, Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 3 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $41 |
| Astellas Pharma US Inc | 1 | $34 |
| Genentech USA, Inc. | 2 | $29 |
| Exact Sciences | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| AstraZeneca | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| Biogen | 1 | $19 |
| Braeburn Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Boston Scientific | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$3,961 in reported general payments places this provider in the 90th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 90 | $70,095 |
| MounjaroTirzepatide | 62 | $67,968 |
| OzempicSemaglutide | 53 | $67,907 |
| FarxigaDapagliflozin Propanediol | 92 | $67,134 |
| JardianceEmpagliflozin | 40 | $42,616 |
| TrulicityDulaglutide | 39 | $40,130 |
| JanuviaSitagliptin Phosphate | 51 | $35,963 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $31,691 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $16,440 |
| InvokanaCanagliflozin | 24 | $13,760 |
| XareltoRivaroxaban | 17 | $10,576 |
| Xigduo XrDapaglifloz Propaned/Metformin | 16 | $9,911 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $9,547 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,691 |
| Olanzapine | 53 | $7,590 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $94 | $115,688154 claims |
| PfizerEliquis, Premarin | $106 | $74,195101 claims |
| Novo NordiskOzempic | $140 | $67,90753 claims |
| AstraZenecaFarxiga | $28 | $67,13492 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta | $11 | $65,15383 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $90 | $12,37224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 803 family medicine providers in Idaho.
Other family medicine in Rigby
- Mark TurnerMeridian$40.5M
- David ButukMeridian$15.2M
- Gary SoucieBlackfoot$5.8M
- Brock McConneheyBoise$4.5M
- William LaitinenMiddleton$1.1M
- Diane McConneheyBoise$681K
- Flint PackerIdaho Falls$587K
- Paul BeckettBlackfoot$344K
- Elaine DavidsonMeridian$303K
- Kenneth CongerSandpoint$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.